EFFECTS OF TRYPANOCIDAL DRUGS ON THE FUNCTION OF TRYPANOSOMES (U) COLORADO STATE UNIV FORT COLLINS DEPT OF PATHOLOGY G C HILL 01 SEP 78 DAMD17-74-C-4046

UNCLASSIFIED
EFFECTS OF TRYPANOCIDAL DRUGS ON THE FUNCTION OF TRYPANOSOMES

Annual Progress Report

George C. Hill

September 1978

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21701

Contract No. DAMD17-74-C-4046

Colorado State University
Fort Collins, Colorado 80523

DOD DISTRIBUTION STATEMENT

Approved for public release; distribution limited

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.
**Title**: Effects of Trypanocidal Drugs on the Function of Trypanosomes

**Author**: George C. Hill

**Performing Organization**: Colorado State University

**Program Element, Project, Task Area & Work Unit Numbers**: 62770A, 3M162770A802.00.051

**Report Date**: September 1, 1978

**Number of Pages**: 88

**Security Class**: Unclassified

**DISTRIBUTION STATEMENT (of this Report)**: Approved for public release; distribution unlimited

**Abstract**: The purpose of this study has been to determine the effects of trypanocidal drugs on the function of trypanosomes. We have also been interested in determining the mode of action of trypanocidal drugs. Our approach to resolving this problem includes investigating various enzymes in host and trypanosomes, studying the effects of trypanocidal drugs on enzyme systems isolated from trypanosomes and studying the structure and transcription ability of purified kinetoplast DNA. We are interested in determining the reason for the unique selective toxicity of known trypanocidal drugs.

**Keywords**: Cultured-infective trypomastigotes; T. rhodesiense; T. brucei; berenil; suramin; L-a-GP-oxidase; macromolecular synthesis.
Our primary results during this past year are:

a. Established two strains of Trypanosoma brucei (T. brucei EATRO 110, and T. brucei 427) in vitro as cultured infective trypomastigotes (1);
b. Established T. rhodesiense EATRO 1895 in vitro as cultured infective trypomastigotes (2);
c. Established T. equiperdum ATCC 30023, a naturally occurring dyskinetoplastic trypanosome, in vitro as culture infective trypomastigotes;
d. Measured the inhibition of RNA and protein synthesis in T. brucei treated in vivo with berenil and suramin;
f. Isolated purified nuclear and kinetoplast DNA from T. rhodesiense for hybridization with nuclear and mitochondrial RNA.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td>1</td>
</tr>
<tr>
<td>Approach to the Problem</td>
<td>2</td>
</tr>
<tr>
<td>Background</td>
<td>4</td>
</tr>
<tr>
<td>Results and Discussion</td>
<td>10</td>
</tr>
<tr>
<td>Conclusions</td>
<td>29</td>
</tr>
<tr>
<td>Recommendations</td>
<td>30</td>
</tr>
<tr>
<td>References</td>
<td>32</td>
</tr>
<tr>
<td>Appendix Including Figures and Tables</td>
<td>35</td>
</tr>
</tbody>
</table>
ABSTRACT

The purpose of our studies has been to determine the effects of trypanocidal drugs on the function of trypanosomes. We have also been interested in determining the mode of action of trypanocidal drugs. Our approach to resolving this problem includes investigating various enzymes in trypanosomes, studying the effects of trypanocidal drugs on enzyme systems isolated from trypanosomes and studying the structure and transcription ability of purified kinetoplast DNA. We are interested in determining the reason for the unique selective toxicity of known trypanocidal drugs.

Our primary results during this last year are:

a. Established two strains of *Trypanosoma brucei* (T. brucei EATRO 110, and T. brucei 427) in vitro as cultured infective trypomastigotes (1);
b. Established *T. rhodesiense* EATRO 1895 in vitro as cultured infective trypomastigotes (2);
c. Established *T. equiperdum* ATCC 30023, a naturally occurring dyskinetoplastic trypanosome, in vitro as cultured infective trypomastigotes;
d. Measured the inhibition of RNA and protein synthesis in *T. brucei* treated in vivo with berenil and suramin;
e. Measured reduced berenil and increase αGP oxidase activity in *T. brucei* treated in vivo with suramin;
f. Isolated purified nuclear and kinetoplast DNA from *T. rhodesiense* for hybridization with nuclear and mitochondrial RNA.
APPROACH TO THE PROBLEM

Our approach to the problem of developing effective trypanocidal drugs is to study two specific and related areas of the biochemistry of trypanosomes, nuclear and mitochondrial gene expression. The interrelationships of these two systems can be seen in Figure 1. In addition, we are concerned with the regulation and control of the functioning of the terminal oxidases in bloodstream trypomastigotes. In order to identify targets for potential trypanocides, we must learn more about the properties of the mitochondrion in trypanosomes including the replication and transcription of KDNA and the repression and synthesis of mitochondrial electron transport systems. We also need to study the properties of the \( \alpha \)-GP oxidase system. If we can alter the functioning of the mitochondrion or other essential electron transport systems in trypanosomes, we should be able to inhibit the continuation of the life cycle of the trypanosome.

We are also interested in the inhibition of novel enzymes on processes which are under control of the nuclear genome. These include processes such as antigenic variation, synthesis of L-\( \alpha \)-GP oxidase, synthesis of cytoplasmic ribosomes or other enzymes or processes. Our goal in the development of novel trypanocidal drugs is to gain additional knowledge on the control mechanisms involved in the transcription of nuclear and mitochondrial genes in these organisms. In this way, we hope to identify potential targets for trypanocides that so far have not been investigated. The proper establishment of the primary mode of action of a drug requires a systematic study of its effect on the various metabolic processes of the cell at the lowest concentrations that inhibit growth. Only when such a survey is
complete can it be concluded confidently that a particular pathway or reaction is most sensitive to inhibition by a drug and is therefore the primary target of that drug. We are carrying out this type of systematic study with several trypanocidal drugs including berenil, suramin, antrycide and ethidium bromide. These types of studies have only rarely been performed with trypanocidal drugs.

The numerous and necessarily speculative points raised in any discussion of trypanocidal drug action are now mostly capable of experimental verification with currently available techniques and data from related fields of cell biochemistry. Given the necessary attention, this largely neglected but important field should yield results of considerable value, not only for an understanding both of trypanocidal drug action and of trypanosomal metabolism, but for cell biology in general. This is the purpose of this contract. So far as trypanocidal drug design is concerned, the era of intelligent empiricism is unlikely to be superseded until the balance of effort and expenditure on drug production is adjusted more favorably in the direction of research on the metabolism of trypanosomes and on the mechanisms whereby existing drugs exert their specific effects.

In developing new trypanocidal agents, we are investigating:

1. The effects of trypanocidal drugs affecting enzyme systems in trypanosomes in hosts;
2. Detailed comparisons of homologous enzymes in host and trypanosomes;
3. Unique cell components or metabolic pathways in trypanosomes;
4. The basis of the selective toxicity of known drugs.
THE BACKGROUND

African trypanosomiasis is confined to Africa by the distribution of its vectors. *T. gambiense* infection occurs over a broad belt from Senegal in the west to the great lakes Victoria, Albert, Benguelo, and Tanzania in the east, extending as far south as north Angola. *T. rhodesiense* is located in east and central Africa and is scattered over a longitudinal band from the south Sudan to Mozambique. The importance of trypanosomiasis of man and animals in Africa has been summarized recently by Kershaw (3) in the statement:

"The World Health Organization in determining the ten major health problems facing mankind places trypanosomiasis of man and his domestic animals high on the list along with malaria, cancer and heart diseases."

Identification of New Trypanocidal Drugs

The need for new trypanocides cannot be overemphasized. At present, chemotherapy of African trypanosomiasis is dependent on a relatively small number of synthetic drugs. Suramin and pentamidine are used for prophylaxis and treatment of early stages of the disease in man. Organic arsenicals such as trypsamide and melaminyl compounds are used for advanced cases, when trypanosomes have invaded the central nervous system. The disease in cattle and other domestic animals is controlled by quaternary ammonium trypanocides (e.g., antrycide, ethidium, prothidium, and related drugs) and by the aromatic diamidine, berenil. As pointed out recently by Newton (4), resistance has been reported to occur against all these drugs and development of resistance to one compound is often accompanied by cross-resistance to another.
In human trypanosomiasis, there is still an urgent requirement for a cheap, simply administered and well-tolerated, preferably "one-shot" drug which would be as effective a prophylactic as pentamidine and active therapeutically against all stages of the infection in both Gambian and Rhodesian sleeping sickness. It should also be incapable of inducing drug resistance and active also against strains with acquired resistance to other drugs.

Possibly the two requirements of prolonged tissue retention (for prophylaxis) and ability to penetrate into the central nervous system are mutually exclusive, but with increasing knowledge of the structure and function of the so-called "blood-brain barrier," this problem should not be insuperable.

In none of the active drugs is the mode of action precisely known. An excellent review on the mode of action of trypanocidal drugs has been prepared by Williamson (5). More recent studies have suggested that berenil and ethidium bromide form complexes with DNA. In the case of ethidium, it is clear this drug is a potent and selective inhibitor of DNA synthesis. It has been shown by several investigators that both phenanthridines and acridines combine with DNA by the heterocyclic chromophore of the drug molecule becoming inserted, or intercalated, between the adjacent base pairs in the double-stranded helix of DNA. Such intercalation is achieved by a partial uncoiling of the DNA helix which results in the base pairs above and below the bound drug molecule becoming separated by twice their normal distance (4).

More recently, it has been shown that phenanthridines also bind to supercoiled DNA of the type found in certain tumor viruses, mitochondria
of many cell types and kinetoplast of trypanosomes. There is evidence that these drugs bind preferentially to such DNA in vivo and give rise to dyskinetoplastic trypanosomes (6) and "petite mutants" of yeast (7). The molecular basis of this preferential binding is not yet fully understood. The findings that have been observed could adequately explain the growth inhibitory activity of phenanthridine drugs but it remains to be established whether their primary action on bloodstream forms of trypanosomes is to inhibit DNA synthesis.

Berenil, an aromatic diamidine, has been shown to interact with DNA and can selectively block kinetoplast replication (8, 9). The earliest reported effect observed of berenil is the localization in the kinetoplast of T. brucei. This has been detected by ultraviolet microscopy with an hour of a curative dose being injected intraperitoneally into infected mice and within seconds of the drug being added to an in vitro suspension of trypanosomes (9). Recent work has shown that berenil can form complexes with purified DNA, but in contrast to phenanthridines, there is good evidence that the complexes are not formed by intercalation (10).

A detailed examination of kinetoplast DNA isolated from berenil-treated T. cruzi has shown that many of the small circular DNA molecules appear as branched structures (8). These forms, which are thought to be replicative molecules, are rarely seen in control preparations, suggesting that berenil does not block the replication of kinetoplast DNA at initiation but binds preferentially to certain specific points in the circular DNA molecule. As for phenanthridines, it cannot be said what is the primary effect of berenil or other diamidines on trypanosomes.
The mode of action of suramin remains enigmatic even after more than a half century of use. In vitro exposure to trypanosomes to suramin at concentrations as low as $10^{-5}$ M is known to reduce their infectivity whereas concentrations as high as $10^{-2}$ M do not affect the motility or respiration of cells. As would be expected from its structure, the drug binds avidly to basic proteins and is known to inhibit many isolated enzymes (5). The most sensitive enzymes examined appear to be hyaluronidase, inhibited at $10^{-5}-10^{-6}$ M, fumarase, inhibited at ca. $10^{-7}$ M, urease at pH 5 (ca. $10^{-4}$ M), hexokinase ($10^{-4}-10^{-5}$ M), and RNA polymerase ($10^{-5}$ M) (11).

Recent studies by our laboratory supported by this contract (12) and other investigators (13, 14) have demonstrated that suramin also inhibits the L-a-GP oxidase in bloodstream trypanosome in vitro. Whether this is its mode of action in vivo remains to be determined.

The ready absorption of this drug by plasma proteins may well account for the long retention time of the compound in man and animals and contribute to its value as a prophylactic agent. The question of how a molecule as large as suramin enters trypanosomes is an interesting one and it seems possible that, when protein bound, suramin actively stimulates pinocytosis. As with the other drugs that we have discussed, there is evidence that suramin becomes localized in lysosomes. Again whether this is important to the trypanocidal action of the drug or whether it is a secondary phenomenon is unknown.

The Importance of African Trypanosomiasis as a Public Health Problem

Human trypanosomiasis, causing sleeping sickness, and animal trypanosomiasis, affecting cattle and other domesticated animals, are the two classical notorious plagues of Africa rooted in the continent since time immemorial.
Sleeping sickness constitutes a permanent and serious risk to the health and well-being of at least 35 million people, and animal trypanosomiasis is the main obstacle to the development of the vast potential for livestock production in the continent. Any involvement of our military troops in areas endemic with African trypanosomiasis would be disastrous.

Ten thousand new cases of human trypanosomiasis are known to occur yearly, but this figure does not truly reflect the importance of the disease as a public health problem. As for many tropical diseases, prevalence figures are underestimates due to failure to recognize the disease and to under-reporting. The relatively low prevalence is due to the major control efforts which have been made over the past 50 years. Without these, sleeping sickness would still be a major cause of death, as it was at the turn of the century, with great epidemics raging along the Congo river and the northern shores of Lake Victoria costing the lives of some 750,000 people.

At the present time, some 10 million people at risk are examined annually by mobile teams at an estimated cost of 5 million dollars. Expenditure for control of tsetse flies is at least ten times higher, but the total is difficult to evaluate since most efforts are directed towards control related to animal disease.

In view of the potential serious danger of sleeping sickness, national health services accord high priority to control services but efforts are frequently inadequate since sufficient resources in terms of finance, manpower and administrative facilities may not be available.
An outbreak of sleeping sickness is a dramatic event in a community since the disease causes severe symptoms due to lesions of the central nervous system and is fatal if not treated. Outbreaks may cause populations to abandon villages and fertile farmlands, and the effect is such that even after two generations, fear of re-exposure may prevent the people from returning.

Current control measures do not usually eliminate the disease; moreover, they are costly and cumbersome. With the available tools, control is a continuing effort, producing suppression rather than eradication. The experience of the past 50 years has been that whenever control efforts are interrupted, for example due to political or economic circumstances, or out of complacency, a flare-up of the disease will sooner or later occur.

A recent example was the resurgence of trypanosomiasis in Zaire in the early 1960's, when after six years of interruption of surveillance, prevalence figures rose from 0.01% to 12%, and even to 18% in some areas. Outbreaks of unknown severity are now reported from Angola, Cameroon and the Sudan. It is to be expected that more outbreaks will occur in coming years unless improved control measures can be found.

Development of new tools is therefore a matter of urgency, not only as a means to eradicate the disease but to provide measures which are more effective and can be more widely applied than those presently available.
RESULTS AND DISCUSSION

A. Cultivation of Trypanosomes In Vitro

During this past year, one of our primary goals has been to develop a culture system for T. brucei and T. rhodesiense cultured infective trypomastigotes. We have been successful in growing in vitro cultured infective forms of:

a. T. brucei 427
b. T. brucei EATRO 110
c. T. rhodesiense EATRO 1895
d. T. equiperdum ATCC 30023

All of the organisms have been initiated and maintained on Chinese hamster lung tissue culture cells. The results with T. rhodesiense have been discussed in a manuscript to be published shortly in Science. The results with T. brucei shall be published shortly in Acta Tropica. Preprints of the manuscripts are included in the appendix.

Using primarily T. brucei and T. rhodesiense, it has been possible for us to develop a culturing system which will be further refined as our research progresses. Infective forms of T. brucei and T. rhodesiense have been initiated and maintained in vitro at 37°C over Chinese hamster lung and buffalo lung tissue culture cells. In the following section, we shall discuss the progress made in the initiation, maintenance and characterization of this in vitro system.

Tissue Culture Cells

The tissue culture cell lines that we have used include buffalo (Bison bison) lung tissue culture cells (ATCC CCL 40, BV, IMR-31) or Chinese
hamster (Cricetulus griseus) lung tissue culture cells (ATCC CCL 16 Don). As noted, both of these lines are available from the American Type Culture Collection (ATCC), Rockville, MD. Thus, it is possible to use commercially available tissue culture cell lines for maintaining the infective forms, a distinct advantage over the procedures required for obtaining the bovine fibroblast-like cell line used by Hirumi et al. (15).

The Chinese hamster lung and buffalo lung cell lines were maintained in HEPES-buffered Rosewell Park Memorial Institute (RPMI) 1640 medium with 20% heat inactivated fetal bovine serum (FBS). Both of these components were obtained from GIBCO, Grand Island, NY and K-C Laboratories, Kansas City, MO respectively. The medium also contained per 100 ml, penicillin - 10,000 U, fungizone - 25 ug, streptomycin - 10 mg and kanomycin - 12.5 ug. The morphology of both tissue cell lines was fibroblast-like and a description of the cell lines is available from ATCC. When maintained at 37°C in an atmosphere of 5% CO₂-95% air, an inoculum of 1.8 x 10⁶ viable tissue culture cells multiplied 3-5 fold in 7 days. The tissue culture cells were used just prior to becoming confluent, usually 3-4 days after a flask was inoculated. Stabilates of both tissue culture cells have been prepared in 10% glycerol.

Preparation of Trypanosomes for Culture

Successful cultures with T. brucei 427, T. brucei EATRO 110, or T. rhodesiense EATRO 1895 were obtained using the following procedures for the preparation of the trypanosomes. Irradiated rats (800 rads) were inoculated with 2 x 10⁶ trypanosomes. With both organisms, the cell population was 90-95% slender forms. When the parasitemia reached a level of 1-5 x 10⁸ trypanosomes/ml three to four days later, the rat was bled
by cardiac puncture. The trypanosomes were centrifuged at 1025 g and the
buffy coat removed. Special precautions were taken to prevent the removal
of red blood cells below the buffy coat. The trypanosomes were washed
twice with Hank's balanced salt solution with 5% sodium citrate. The
trypanosomes were then inoculated into a total of 5.0 ml of medium (RPMI
and 20% FBS containing the previously mentioned antibiotics) in T-25
flasks or 15.0 ml in T-75 flasks. Most successful experiments occurred
in those initiated in the T-75 flasks.

Initiation of *T. brucei* Cultures

An experiment with *T. brucei* was performed by inoculating a T-75
flask of buffalo lung cells with an initial concentration of $8 \times 10^4$
trypanosomes/ml. The trypanosomes were incubated at 37°C in an atmosphere
of 5% CO$_2$ - 95% air in the medium described. Two days later, a third of
the medium was changed. The trypanosomes remained at a low count, less
than $1 \times 10^5$ cells/ml for the next four days. The cell numbers then began
to increase and on day 8 reached a cell count of $5 \times 10^5$ cells/ml. One-third
of the medium was then changed daily and on day 11, the cell count was
$2.5 \times 10^6$ cells/ml. By changing one-third of the medium daily, the cells
have been maintained subsequently at a concentration of 2-4 x $10^6$ cells/ml.
In recent experiments, it is clear that 5% CO$_2$ is not necessary in order
for the trypanosomes to grow. These results can be seen in Table I.

It was also possible to initiate flasks after incubation of the trypano-
somes from irradiated rats in the medium at 25°C for 24 hours prior to
adding the trypanosomes to the tissue culture cells at 37°C. Cells maintained
for up to three days at 25°C in the described medium were as infective as
controls for mice and rats. In addition, 20-30% of the cells were observed dividing on day 2 and day 3. These results were discussed in the Annual Report provided 1 January, 1978.

Additional cultures from the original buffalo lung flask were initiated on either buffalo lung cells or Chinese hamster lung cells. The flasks were usually initiated at 2 x 10^5 cells/ml. The results of a typical experiment on Chinese hamster lung cells are presented in Table II. On day 3 after inoculation, with one-third of the cell medium changed daily the cell count was 2.1 x 10^6 cells/ml, reflecting a population doubling time of 12 hours. The daily trypanosome count for *T. brucei* 427 continued at 1.0-3.0 x 10^6 cells/ml until the tissue cells had to be changed. *T. brucei* EATRO 110 grows slightly higher (Table III). The trypanosomes were changed to fresh tissue culture cells every 7 days. However infective forms of trypanosomes were maintained in older cultures for 20-30 days, depending on the age of tissue culture cells.

**Initiation of *T. rhodesiense* Cultures**

*T. rhodesiense* was initiated in culture using similar procedures as described for *T. brucei*. However, the trypanosomes were initiated on Chinese hamster lung tissue culture cells. The trypanosome numbers remained low, less than 1 x 10^5 cells/ml for 10 days. Then the numbers increased to 5 x 10^5 cells/ml on day 12. One-third of the medium was then changed and a new flask started at 4 x 10^5 cells/ml. The flask then began to increase markedly. The results of the growth of trypanosomes in a new flask initiated at this point are given in Table IV. Under identical cultural conditions, *T. rhodesiense* grows faster than *T. brucei*. With one-third of the medium changed daily *T.
rhodesiense has been maintained in culture at $3-5 \times 10^6$ cells/ml. The population doubling time for T. rhodesiense is 9-11 hours.

**Growth of Trypanosomes In Vitro**

The trypanosomes grow not only in the medium but also in spaces between the tissue culture cells. In figure 2, one can observe T. brucei 427 on buffalo lung tissue culture cells. Figure 3 provides similar results for T. brucei EATRO 110 which often grows very close to the tissue culture cells. With all strains of trypanosomes, organisms are often observed in the spaces between the tissue culture cells. In addition, trypanosomes can be seen swimming free in the medium. In the case of T. rhodesiense, the trypanosomes also grow close to the tissue culture cells as well as free in the medium (figures 4 and 5).

**Morphology of Trypanosomes In Vitro**

The morphology of trypomastigotes maintained by rapid passage at 24 hours intervals in cultures was identical to that of the long sledge forms of T. brucei or T. rhodesiense observed in the bloodstream in vivo. Few stumpy forms were observed and as can be seen in figures 6A and B, the cultured trypanosomes had subterminal kinetoplasts. In addition, some bizarre forms were observed in culture. The bizarre forms were particularly present in cultures with older tissue culture cells and were also observed by Hirumi et al. (15) in their cultures. As seen in Giemsa stain preparations, these forms appear to be multinucleate with many membranes present. Often these forms were seen dividing.

The ultrastructural studies of the trypanosomes provided excellent evidence that the cultured infective trypanosomes had a fine structure
similar to the bloodstream trypomastigotes. The ultrastructure of *T. brucei* is reported in the *Acta Tropica* paper in the appendix (1). See figures 1-3 in this manuscript. It was identical to *T. rhodesiense* which we shall discuss in more detail. The surface coat can be clearly seen on the *T. rhodesiense* cultured infective trypomastigotes (figures 7-10). It can be easily seen in figure 9 and 10. In figure 8, the mitochondrion with few cristae can be observed. This is a characteristic of salivarian slender bloodstream trypomastigotes. Figure 11 is an electron micrograph of a *T. rhodesiense* bloodstream trypomastigote. Note the presence of the thick surface coat. In addition, figures 12-14 are *T. rhodesiense* procyclic trypomastigotes with the surface coat absent.

It is clear from these studies that the *T. rhodesiense* cultured infective trypomastigotes have identical fine structure to the bloodstream trypomastigotes and are different from the procyclic trypomastigotes.

**Terminal Respiration of Cultured Trypanosomes**

Slender trypomastigotes have an α-GP oxidase which is sensitive to SHAM (figure 15). In order to provide further evidence that the cultured infective trypomastigotes were slender bloodstream trypomastigotes, we have studied the steady state oxidases in these cultured forms. Ninety ml of culture fluid of *T. rhodesiense* from inoculated Chinese hamster lung cell cultures were harvested at a concentration of $2.5 \times 10^6$ trypansomes/ml. The organisms collected by centrifugation and the steady state oxygen levels observed. The results are given in figure 16. Salicylhydroxamic acid (SHAM) inhibited 90% of the cell respiration. Azide had little effect, inhibiting 7% of the cell respiration. Little significant azide and SHAM insensitive respiration
was observed. Similar results were obtained for cultured infective trypomastigotes of *T. brucei* (1). These results provide evidence that the SHAM sensitive α-GP oxidase is the predominant terminal oxidase in trypomastigotes cultured in our system. In addition, we can distinguish cultured infective trypomastigotes from procyclic trypomastigotes which have little SHAM-sensitive respiration and a significant azide-sensitive respiration (figure 17). These differences are clearly presented in Table IV.

**Infectivity of Cultured Trypanosomes**

Experiments to test the infectivity of the cultures of *T. brucei* or *T. rhodesiense* were performed with stabiltases of bloodstream trypomastigotes as controls. The mice were the descendents of a four-way cross of four inbred strains, DBA/2 CIJax, C57Bl/6 and BALB/c. In one such experiment, they were inoculated with $1 \times 10^4$, $1 \times 10^5$ and $1 \times 10^6$ *T. brucei* trypanosomes which had been in culture for 20 days. The results of the experiment are given in figure 18. Infectivity tests were also performed on non-irradiated mice at day 17, 24, 30, 33, 40 and 44. The cultures all produced patent infections. These cultures continue to grow and are infective to mice after 80 days in culture.

In similar experiments, the cultures of *T. rhodesiense* have also produced infections in mice. Mice infected with $1 \times 10^6$ cells produced patent infections 4-5 days post-inoculation Table VI. These cultures continue to be infective to mice after 80 days in culture.

Studies on the infectivity of the cultured trypomastigotes have demonstrated that all the organisms maintained in culture are infective to mice and rats. These organisms include *T. brucei* 427, *T. brucei* EATRO
110, *T. rhodesiense* EATRO 1895 and *T. equiperdum* ATCC 30023. However, several differences between the culture and bloodstream trypomastigotes have been observed.

1. In all the organisms studied, during the first 20-25 days in culture, the time necessary to kill mice is the same as controls;

2. After the first three weeks, the cultured trypomastigotes develop parasitemia at the same time as control but require a longer period before the mice die. Low parasitemias are maintained for 20-40 days and a large amount of variation occurs. However, *T. brucei* EATRO 110 is an exception. After 50 days in culture, we have observed no difference in comparison to the controls.

3. All cultured organisms are infective to rats but the parasitemias of the cultured trypomastigotes are very low and rarely kill the host.

We now need to determine what is the reason for the reduced parasitemia after growth in culture. This is an extremely important question and may assist us in developing new knowledge against African trypanosomiasis.
B. Effects of Various Drugs on Bloodstream Trypomastigotes

Our efforts have been devoted to an examination of *T. brucei* treated *in vivo* with several trypanocidal drugs including suramin, ethidium bromide, berenil and antrycide. The criteria we have considered includes:

a. effects on fine structure;

b. effect on RNA and protein synthesis;

c. effect on continued development on parantemia;

d. effect on cell respiration.

Hadjuk (16) has written an excellent review on the influence of DNA complexing compounds on the kinetoplast of trypanosomatids. In the literature reviewed, there are numerous experiments using insect trypanosomatids or bloodstream organisms *in vitro*. Amazingly, there are few, if any, studies reported which study the biochemical effects of trypanocidal drugs of trypanosomes treated *in vivo*. A few studies have been performed on the ultrastructure of trypanosomes isolated from any drug-treated hosts (17, 18), but biochemical studies are lacking.

During the past year, we have continued these studies with *T. brucei*. In our experiments, after the parasitemia level reached a level of 5-10 x 10^8 trypanosomes/ml, the rats were treated at 10 mg/kg with trypanocidal drugs (e.g., antrycide, suramin, ethidium bromide and berenil). After the parasitemia had been reduced 20-30% by the various drugs, the trypanosomes were separated from the blood by centrifugation, washed with an isotonic buffer, and used in the biochemical experiments. Table VII provides the protocol for such an experiment. The fine structure, respiration and RNA and protein synthesis
information was obtained from such an experiment.

Cells treated with berenil (10 mg/kg), as observed in a tail vein blood smear, were markedly affected morphologically after only 15-20 minutes exposure to the drug. The trypanosomes became elongated and noticeably sluggish. When these trypanosomes were harvested, they had a distinct yellow color in contrast to the white pellet of the control. The ethidium bromide pellet had a faint pink appearance. All other pellets from drug treated cells appeared as the controls.

Effect on Fine Structure

In the ultrastructural studies, the trypanosome pellet was fixed in 4% glutaraldehyde in 0.1 M sodium cacodylate buffer. The organisms were post-fixed with 2% OsO₄, dehydrated and stained with lead acetate. A comparison of the ultrastructure of the cells in table VII provided information on the effects of trypanocidal drugs on the fine structure of the drug-treated trypanosomes. The berenil treated cells were markedly affected (figures 19-21). There was an effect on the kinetoplast DNA (figure 19) as well the nuclear DNA (figures 20 and 21). Figure 21 provides clear demonstration of the nucleus in various stages of degradation after treatment with berenil. These results and the fact that they are observed within 15 minutes strongly suggest the effect of berenil is not specific to KDNA. In addition, figure 22 demonstrates that the parasitemia after treatment with berenil is reduced dramatically after 2 hours, a result not likely if the effect of the drug were only on KDNA. The period required for decrease is less than the population doubling time of the trypanosomes (e.g., 4-6 hours) a mode of inhibition of berenil not specific for KDNA.
In the case of ethidium bromide, after exposure of the trypanosomes for two hours, no specific effect was observed. Both the kinetoplast DNA (figures 23 and 24) and nuclear DNA (figure 25) was affected. Antrycide has a marked effect on the population of ribosomes as well as the cytology of the cell (figure 26). Even though the parasitemia decreased after 12-14 hours exposure to suramin (figure 27), no effect on the ultrastructure of the trypanosomes was observed in comparison to the controls (figure 28).

Williamson and co workers (17, 18) have also studied the fine structure of trypanosomes exposed to trypanocidal drugs \textit{in vivo} and observed several effects. They concluded that the kinetoplast is the principal focus of berenil action. Similar studies by these investigators have shown that curative dosages of antrycide on bloodstream trypanosomes cause the same type of KDNA condensation, after 5-6 hours, as seen in diamidine (berenil and hydroxystilbamidine) treated cells (19, 20). These observations suggest that antrycide binds preferentially to the KDNA \textit{in vivo} and alters the structural organization of the KDNA network.

**Effects on RNA and Protein Synthesis-Exposure to Drugs In Vivo.**

The effect of these trypanocidal on the synthesis of RNA and protein was also investigated. The trypanosomes were harvested as described in the previous experiment and then resuspended in RPMI medium with 5% FBS to 2 x 10^8 cells/ml in a total of 5 mls. The trypanosomes were then labelled with 25 mCi (5 mCi/ml of either or $^3$H uridine for RNA synthesis or $^3$H leucine for protein synthesis). Samples were taken at time points 0, 10, 20, 30, 40, 50 and 60 minutes. These were then precipitated and filtered with 5% TCA and read in the liquid scintillation counter for 10 minutes with 3% error. The
results are presented in tables VIII and IX and figures 22 and 23.

Berenil had a marked effect on RNA synthesis, inhibiting uridine incorporation 87.2% + 3.7 S.E. In addition, protein synthesis was inhibited 30.1% + 2.3 S.E. Results with antrycide and ethidium bromide can also be seen in figures 29 and 30. Antrycide markedly inhibited protein synthesis (table IX). The other drug that was studied extensively was suramin. Treatment with suramin at 10 mg/kg for 12-13 hours under the same experimental procedures reveals a 2% decrease in the average leucine incorporation and 88.3% decrease in the average uridine incorporation. Our results show that suramin drastically inhibits the synthesis of RNA by the trypanosomes and has little effect on protein synthesis.

As previously mentioned, when bloodstream *T. brucei* is exposed *in vivo* to berenil (10 mg/kg), the trypanosomes become elongated in 15-30 minutes. This same effect has been noted *in vitro* when control bloodstream trypomastigotes are removed from the rat or cultured infective trypomastigotes are exposed to 5-10 µg/ml. In each case, the effect is observed in 80-90% of the cells 1-2 hours after the organisms are incubated at 37°C in RPMI 1640 medium plus 20% FBS. These results demonstrate some of the effects of berenil seen *in vivo* with *T. brucei* can be observed *in vitro*. No morphological effect has been observed *in vitro* with procyclic trypomastigotes. Experiments are now required to accurately measure the amount of berenil and ethidium bromide that binds to those organisms over a specific period of time.

**Effects on RNA and Protein Synthesis—Exposure to Drugs In Vitro**

Along with our studies on the effects of trypanocidal drugs on RNA and protein synthesis in trypanosomes, we have been investigating the effects of
various metabolic inhibitors (e.g., chloramphenicol, cyclohexamide, ethidium bromide and actinomycin D) on *T. brucei*. We have now identified media for excellent incorporation and growth of trypanosomes *in vitro*, thus enabling an investigation of the RNA and protein synthesis *in vitro* to occur. The SM medium of Cunningham (21) is excellent for procyclic trypanastigotes and the RPMI medium is excellent for bloodstream trypanastigotes. Few studies have been reported under ideal conditions. In addition, because of the known mode of action of these inhibitors (figure 1), the response of both procyclic and bloodstream trypanastigotes is important.

Trypanosomes were incubated at $5 \times 10^7$ ml in 2.5 ml of medium. As noted, for bloodstream trypanastigotes, RPMI plus 5% fetal bovine serum (FBS) was used. For procyclic trypanastigotes, SM medium plus 5% FBS was used. The RNAs and proteins were labeled with $^{3}H$ uridine and $^{3}H$ leucine respectively. The RNAs or proteins synthesized were precipitated with TCA and counted.

Results with ethidium bromide provide a clear difference between procyclic and bloodstream trypanastigotes of *T. brucei* EATRO 110. After 60 minutes incubation in the presence of ethidium bromide, procyclic trypanastigotes required three-fold more ethidium bromide in comparison to bloodstream trypanastigotes in order to inhibit 50% of the RNA synthesis. As seen in figure 31, bloodstream trypanastigotes are clearly more sensitive to ethidium bromide than procyclic trypanastigotes.

In order to determine the contribution of cytoplasmic and mitochondrial protein synthesis in *T. brucei* procyclic and bloodstream trypanastigotes,
we have been investigating the inhibition by chloramphenicol and cyclohexamide. In procyclic trypomastigotes, the maximum inhibition with cyclohexamide is 85.6% at levels between 100-300 μg/ml (0.4 - 1.1 mM). In contrast, chloramphenicol inhibits protein synthesis 18-22% at concentrations of 100-200 μg/ml (0.31 - 0.62 mM). Concentrations of chloramphenicol higher than 0.62 mM kill the trypanosomes. This concentration is considerably less than 50 mM (14.1 mg/ml) concentration recommended for T. brucei by Hanas et. al. (29). These results would suggest a significant amount of chloramphenicol sensitive protein synthesis (18-22%) occurs in procyclic trypomastigotes. In addition, with high concentrations of cyclohexamide and chloramphenicol, 10% leucine incorporation continues to occur.

In bloodstream trypomastigotes, markedly different results occur. High concentrations of cyclohexamide from 20-200 μg/ml (0.062 mM-0.62 mM) inhibited leucine incorporation in most experiments only 35-45%. The results may be due to the presence of the surface coat preventing penetration of the cyclohexamide. At low concentrations (0.062 mM), chloramphenicol actually stimulated leucine incorporation 15%. At higher concentrations of 0.31-0.62 mM chloramphenicol, 18-25% inhibition of leucine incorporation occurred, quite comparable to the results with procyclic trypomastigotes. Concentration of cyclohexamide or chloramphenicol above 500 μg/ml killed the bloodstream or procyclic trypomastigotes. Results with actinomycin also show a greater sensitivity to this drug by bloodstream rather than procyclic trypomastigotes (Table X).
Effects of Respiration

We have also studied the effects of suramin and berenil on the steady states and total respiration evident after the trypanosomes were isolated from drug-treated rats (Table VII). The purpose of these experiments was to gain additional information on the biochemical mode of action of these trypanocides. The results are presented in table XI. Antrycide and ethidium bromide have little effect on the respiration of the cells. However, suramin-treated cells had a marked increase in respiration. This is surprising since suramin is thought to inhibit the α-GP oxidase in trypanosomes. In contrast, berenil markedly inhibits the respiration of the organisms. This effect occurs as early as 1 hour after treatment with the drug. No difference was observed in the steady state level of various oxidases. Further studies in this area are needed, particularly in order to determine what respiratory enzymes are stimulated after treatment with suramin.
C. **Determination of the Presence of an RNA Transcript.**

Studies to identify an RNA transcript from kDNA from *T. rhodesiense* have continued.

The steps included in this phase of research include the following:

a. Growth of 40 liters of *T. rhodesiense*;

b. Purification of network kinetoplast DNA;

c. Purification of Pst 1 restriction endonuclease;

d. Digestion of network kinetoplast DNA with Pst 1;

e. Purification of RNA's from *T. rhodesiense*;

f. Hybridization of RNA's to nuclear or kinetoplast DNA columns (figure 33).

**Growth of *T. rhodesiense***

The laboratory strain of *T. rhodesiense* (EATRO 1895) has been used and stabilated blood from infected animals has served as the primary source for our investigations. This strain of *T. rhodesiense* was adapted for growth in vitro. Tail vein blood was secured aseptically from rats infected with stabilated organisms. One-hundred microliter drops of the blood were deposited into 2 ml of SM medium (21) and the mixture incubated for 3 days at 27°C. The cells were completely transformed by day 4 and were then diluted into 10 ml of fresh SM medium. The trypanosomes were maintained in this medium by subculturing every 3 days to an initial concentration of 1 x 10⁶ cells/ml. All of our experiments have been conducted with these or similarly adapted cells of *T. rhodesiense* (EATRO 1895).

Amino acid analysis was performed on the SM medium before and after *T. rhodesiense* had grown in it for 7 days (Table XII). Conversion of the
total picrate soluble amino acids to their n-trifluoroacetic acid n-butyl esters was carried out according to Gehrke (22) and analysis was performed by gas chromatography on an ethylene glycol adipate/OV-17: SP-2401 column. Our results were similar to those reported by Cross et al. (23) and Brun and Jenni (24) showing the relative increases in glutamine/glutamic acid, phenylalanine, methionine, serine, proline, glycine and valine. Subsequently, we have modified the SM medium by removing alanine and glycine and by decreasing the glutamine and proline concentrations by one-tenth those indicated by Cunningham (21). Growth of our cells in this modified media (SM*) was comparable to the original medium (SM) and is depicted in figure 32.

In order to isolate 300 mg of maxicircle DNA, we had to obtain 15-20 gm wet weight of *T. rhodesiense* cells, which meant harvesting 40 liters of growth media over a 5 week period. The cells were inoculated into 320 ml of sterile aliquots of SM* medium in Roux bottles at an initial concentration of 1 x 10^6 cells/ml (figure 32). After 2 days at 27°C, the trypanosomes were harvested. The average cell density was 7.0 x 10^6 cells/ml. The sedimented trypanosomes were resuspended in isotonic buffer and pelleted again. Liquid nitrogen was then used to rapidly freeze the washed pellets which were subsequently stored at -70°C.

**Labelling and Isolation of *T. rhodesiense* RNA**

The nucleic acids of *T. rhodesiense* were labelled with ^{32}P in order to aid in the detection, quantitation and characterization of the RNA fractions binding to the mitochondrial DNA-cellulose column. The labelled DNAs will be characterized as to their base composition and hybridized to...
cold RNA fractions with sequence homology. One-hundred ml of SM* medium was inoculated with actively growing cells to an initial concentration of 1 x 10^6 cells/ml. Five millicuries of ^{32}P were added aseptically and the culture was incubated for 3 days at 27°C. The labelled cells were collected by centrifugation at 6,000 rpm at 4°C. The pellets were washed in 25 ml of cold buffer and centrifuged again. The final pellet was rapidly frozen with liquid nitrogen.

The zonal centrifugation procedure of Glisin et al. (25) as modified by Hallick et al. (26) for securing global RNA was adapted for use with this system. Sarkosyl lysates of T. rhodesiense were treated with pronase then adjusted to 1.609 g/ml with solid CsCl. The mixture was then centrifuged over a pad of CsCl at 1.707 g/ml for 16 h at 20°C. Under these conditions, the RNA and network kDNA sediments and nuclear DNA collects at the interface of the two CsCl solutions. The inclusion of aurintricarboxylic acid (AT) in the lytic buffer competitively inhibits nuclease activity.

Purification of Pst I Restriction Endonuclease

It has been shown by several investigators that the restriction endonuclease Pst I frees maxicircles from network kDNA (27). The maxicircles are thought to be the only kDNA component which is transcribed into RNA and will be necessary in our hybridization experiments. Thus, Pst I restriction endonuclease is being purified in our laboratory by the modified technique of Bickle et al. (28). The organism carrying this enzyme was kindly provided for us by Dr. Julian Davis from the University of Wisconsin. Providencia stuartii 164 (Pst I) was grown overnight at 30°C then inoculated into 4 liters of L-Broth. The cells were harvested when they reached an O.D. of 1.1 at 550 nm. The cell pellets were rapidly frozen in liquid
nitrogen and stored at \(-70^\circ\text{C}\) until needed. Frozen pellets were thawed slowly at \(4^\circ\text{C}\) in 2 x volumes of a Tris buffer, then sonicated for a total of 2 minutes at \(4^\circ\text{C}\) using an output of 75 watts/10 sec. For the small volumes used, the temperature change after each burst was monitored and found to increase about 4 degrees. Cooling time in between sonic bursts was 6 mins. This allowed the temperature to return to \(4^\circ\text{C}\) before another cycle was begun. The sonicate was clarified by centrifugation at 100,000 x g for 120 mins. The supernatant fractions were collected and adjusted to 1 M NaCl. This solution was then applied to a BioGel A 0.5 column for fractionation based on size.

A heparin-agarose column was prepared in our lab by activating BioGel A 1.5 with cyanogen bromide then adding excess amount of heparin (100 mg/50 ml settled volume). The dialyzed Pst 1 solution was applied to the column, equilibrated with 0.01 M phosphate buffer and eluted with a linear salt gradient (0.05/0.5 M NaCl) in the same buffer. The active fractions were again collected and dialyzed against phosphate buffer containing 0.2 M NaCl and 50% glycerol. The enzyme was stored at \(-20^\circ\text{C}\) until needed.

Enzyme containing fractions were detected by their ability to hydrolyze DNA to specific size fragments. The DNA was purified in our laboratory from \(E.\ coli\) CSH 45 for this assay. Agarose gel electrophoresis was used to separate the fragments of DNA and demonstrate which fraction contained the restriction endonuclease. The enzyme solution was pooled, dialyzed and stored at \(0^\circ\text{C}\) until it could be applied to the next column. With purified Pst 1, we will be able to proceed to isolate maxicircle DNA from \(T.\ rhodesiense\) and begin our hybridization studies.
CONCLUSIONS

Our primary results during this last year are:

a. Established two strains of *Trypanosoma brucei* (T. brucei EATRO 110, and T. brucei 427) *in vitro* as cultured infective trypomastigotes (1);

b. Established *T. rhodesiense* EATRO 1895 *in vitro* as cultured infective trypomastigotes (2);

c. Established *T. equiperdum* ATCC 30023, a naturally occurring dys-kinetoplastic trypanosome, *in vitro* as cultured infective trypomastigotes;

d. Measured the inhibition of RNA and protein synthesis of *T. brucei* treated *in vivo* with berenil and suramin;

e. Measured reduced berenil and increase αGP oxidase activity in *T. brucei* treated *in vivo* with suramin;

f. Isolated purified nuclear and kinetoplast DNA from *T. rhodesiense* for hybridization with nuclear and mitochondrial RNA.
RECOMMENDATIONS

Our recommendations would be the following:

1. Continue attention to the development of an in vitro system for growing and maintaining cultured-infective trypomastigotes. Our next step should be the establishment of cultures from single cell populations. This would be of value in studying numerous processes in trypanosomes including drug resistance, antigenic variation and nuclear and mitochondrial genes processes. In addition, a long term goal is to grow the trypanosomes in the absence of the feeder cells;

2. Direct attention not only to mitochondrial gene processes but also gene expression at the nuclear level. It is unlikely, that experiments devoted only towards mitochondrial gene expression will resolve all chemotherapeutic efforts. Thus, attention to processes controlled by nuclear genes would also be necessary and extremely important;

3. Continue support for biochemical characterization of trypanosomes obtained from drug-treated rats. This system lends itself to the isolation of trypanosomes which have been treated in vivo with drugs and then can be analyzed biochemically.

4. Novel approaches to the development of trypanocidal drugs are needed. With the advent of new techniques in molecular biology, this should certainly be possible. Some potential targets include the α-glycerophosphate oxidase. Can we develop agents to present the synthesis of this important enzyme? We already know the suramin inhibits its functions. Can we inhibit the synthesis of this important oxidase as well enzymes of the anaerobic pathway? In this
regard, it will be necessary to purify the L-α-CP oxidase and identify the anaerobic pathway before we can begin to identify the genes and mRNAs responsible for their synthesis. This approach is considered in our renewal.

A three-part approach is required. Many more metabolic studies are needed to unravel the biochemical pathways that occur in parasitic protozoa and to identify further potential targets for chemotherapeutic attack. In addition, more research needs to be carried out on the biochemical modes of action of existing drugs and on mechanisms of resistance since such studies not only help to elucidate the metabolism of the organism but also provide information which will be vital to future attempt at more rational drug therapy directed towards specific target sites. As well as these biochemical studies it is essential that the conventional method of finding new drugs, the screening of compounds against parasites in vitro, or in animals, should continue. Information from the other two approaches, as it becomes available, should enable an increasingly more rational approach to be taken in the selection of compounds to be synthesized and tested.
References


TABLE I

GROWTH OF *T. BRUCEI* IN PRESENCE AND ABSENCE OF CO₂

<table>
<thead>
<tr>
<th>Day</th>
<th>Control (^a) (trypanosomes/ml)</th>
<th>Plus CO₂ (^b) (trypanosomes/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.1 x 10⁵</td>
<td>1.0 x 10⁵</td>
</tr>
<tr>
<td>1</td>
<td>6.8 x 10⁵</td>
<td>2.9 x 10⁶</td>
</tr>
<tr>
<td>2</td>
<td>1.6 x 10⁶</td>
<td>2.0 x 10⁶</td>
</tr>
<tr>
<td>3</td>
<td>5.3 x 10⁶</td>
<td>2.4 x 10⁶</td>
</tr>
<tr>
<td>4</td>
<td>3.6 x 10⁶</td>
<td>1.4 x 10⁶</td>
</tr>
</tbody>
</table>

\(^a\) - One-third of the RPMI medium was changed daily in both flasks. The control flask was incubated in 100% air.

\(^b\) - This flask was incubated in 95% air, 5% CO₂.
<table>
<thead>
<tr>
<th>Day</th>
<th>Cell Numbers $^a$ (trypanosomes/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>$1.5 \times 10^5$</td>
</tr>
<tr>
<td>1</td>
<td>$4.0 \times 10^5$</td>
</tr>
<tr>
<td>2</td>
<td>$1.2 \times 10^6$</td>
</tr>
<tr>
<td>3</td>
<td>$2.1 \times 10^6$</td>
</tr>
<tr>
<td>4</td>
<td>$1.9 \times 10^6$</td>
</tr>
<tr>
<td>5</td>
<td>$1.2 \times 10^6$</td>
</tr>
<tr>
<td>6</td>
<td>$1.6 \times 10^6$</td>
</tr>
</tbody>
</table>

$^a$ - One-third of the RPMI medium was changed daily.
TABLE III

GROWTH OF T. BRUCEI EATRO 110

<table>
<thead>
<tr>
<th>DAY</th>
<th>Chinese Hamster Lung</th>
<th>Buffalo Lung</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>$2.0 \times 10^5$</td>
<td>$2.6 \times 10^5$</td>
</tr>
<tr>
<td>2</td>
<td>$7.8 \times 10^5$</td>
<td>$1.5 \times 10^6$</td>
</tr>
<tr>
<td>3</td>
<td>$3.6 \times 10^6$</td>
<td>$4.0 \times 10^6$</td>
</tr>
<tr>
<td>4</td>
<td>$3.3 \times 10^6$</td>
<td>$3.7 \times 10^6$</td>
</tr>
</tbody>
</table>

\textsuperscript{a} One-third of the RPMI medium was changed daily. The counts presented are those before the culture was changed and each represents three replicate samples per day.
TABLE IV

GROWTH OF T. RHODESIENSE ON CHINESE HAMSTER LUNG CELLS

| Day | Cell Numbers<sup>a</sup>  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(trypanosomes/ml)</td>
</tr>
<tr>
<td>0</td>
<td>1.0 x 10&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>1</td>
<td>4.5 x 10&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>2</td>
<td>3.5 x 10&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
<tr>
<td>3</td>
<td>5.4 x 10&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
<tr>
<td>4</td>
<td>3.4 x 10&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
<tr>
<td>5</td>
<td>3.3 x 10&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> One-third of the RPMI medium was changed daily. The counts presented are those before the culture was changed and each represents three replicate samples per day.
<table>
<thead>
<tr>
<th>T. BRUCEI</th>
<th>α-GP STIMULATION</th>
<th>PROLINE STIMULATION</th>
<th>SHAM INHIBITION</th>
<th>AZIDE INHIBITION</th>
<th>AZIDE/SHAM INSENSITIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bloodstream</td>
<td>22</td>
<td>0</td>
<td>78</td>
<td>19</td>
<td>3</td>
</tr>
<tr>
<td>Trypomastigotes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cultured Infective</td>
<td>20</td>
<td>3</td>
<td>86</td>
<td>11</td>
<td>3</td>
</tr>
<tr>
<td>Trypomastigotes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procyclic</td>
<td>13</td>
<td>28</td>
<td>16</td>
<td>66</td>
<td>19</td>
</tr>
<tr>
<td>Trypomastigotes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**TABLE VI**

**INFECTIVITY OF T. RHODESIENSE GROWN ON CHINESE HAMSTER LUNG CELLS**

<table>
<thead>
<tr>
<th>Trypanosomes</th>
<th>Inoculum of Trypanosomes</th>
<th>Days After Inoculum Before Infection Developed&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cultured Infective Trypanosomes</td>
<td>$1 \times 10^6$</td>
<td>4</td>
</tr>
<tr>
<td>Cultured Infective Trypanosomes</td>
<td>$1 \times 10^5$</td>
<td>5</td>
</tr>
<tr>
<td>Bloodstream Stabilates</td>
<td>$1 \times 10^6$</td>
<td>4</td>
</tr>
<tr>
<td>Bloodstream Stabilates</td>
<td>$1 \times 10^5$</td>
<td>5</td>
</tr>
</tbody>
</table>

<sup>a</sup>The T. rhodesiense trypanosomes had been maintained on Chinese hamster lung tissue culture cells for 60 days. The infectivity tests are the results of two different experiments with six mice in each experiment.
TABLE VII

Protocol for Drug Treatment Experiments with *T. brucei*

<table>
<thead>
<tr>
<th>Drug</th>
<th>Amount mg/kg</th>
<th>Parasitemia Level at Treatment cells/ml</th>
<th>Parasitemia Level at Sacrifice cells/ml</th>
<th>Length of Treatment hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Berenil</td>
<td>10</td>
<td>$1.0 \times 10^9$</td>
<td>$6.0 \times 10^8$</td>
<td>$1\frac{1}{2}$</td>
</tr>
<tr>
<td>Suramin</td>
<td>10</td>
<td>$9.3 \times 10^8$</td>
<td>$3.2 \times 10^8$</td>
<td>$12\frac{1}{2}$</td>
</tr>
<tr>
<td>Antryclide</td>
<td>10</td>
<td>$8.4 \times 10^8$</td>
<td>$2.0 \times 10^8$</td>
<td>$12\frac{1}{2}$</td>
</tr>
<tr>
<td>Ethidium Bromide</td>
<td>10</td>
<td>$1.0 \times 10^9$</td>
<td>$7.8 \times 10^8$</td>
<td>2</td>
</tr>
<tr>
<td>Control</td>
<td>0</td>
<td>$1.2 \times 10^9$</td>
<td>$2.0 \times 10^9$</td>
<td>---</td>
</tr>
</tbody>
</table>
TABLE VIII

Inhibition of $^3$H-Uridine Incorporation in T. brucei EATRO 110 In Vitro

<table>
<thead>
<tr>
<th>Drug</th>
<th>Percent Inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethidium Bromide</td>
<td>48.2 ± 4.2</td>
</tr>
<tr>
<td>Antrycide</td>
<td>81.4 ± 3.3</td>
</tr>
<tr>
<td>Berenil</td>
<td>87.2 ± 3.7</td>
</tr>
<tr>
<td>Suramin</td>
<td>88.3 ± 2.5</td>
</tr>
</tbody>
</table>

Infected rats were treated with the trypanocidal drugs at 10 mg/kg. The trypanosomes were isolated at various times as noted in Table V and used to study RNA synthesis. The percent inhibitions presented are the average of three different experiments. Standard errors of these results are also given.
TABLE IX

Inhibition of $^3$H-Leucine Incorporation in *T. brucei* EATRO 110 In Vitro

<table>
<thead>
<tr>
<th>Drug</th>
<th>Percent Inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suramin</td>
<td>0.2 ± 1.5</td>
</tr>
<tr>
<td>Ethidium Bromide</td>
<td>14.2 ± 2.0</td>
</tr>
<tr>
<td>Berenil</td>
<td>30.1 ± 2.3</td>
</tr>
<tr>
<td>Antrycide</td>
<td>64.2 ± 3.2</td>
</tr>
</tbody>
</table>

Infected rats were treated with the trypanocidal drugs at 10 mg/kg. The trypanosomes were isolated at various times as noted in Table V and used to study protein synthesis. The percent inhibitions presented are the average of three different experiments. Standard errors of these results are also given.
TABLE X

Inhibition of RNA Synthesis in *T. brucei* EATRO 110 by Actinomycin

<table>
<thead>
<tr>
<th>Drug Concentration (µM)</th>
<th>Percent Inhibition</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bloodstream Trypomastigotes</td>
<td>Procyclic Trypomastigotes</td>
<td></td>
</tr>
<tr>
<td>3.6</td>
<td>87</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>7.2</td>
<td>89</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>35.6</td>
<td>91</td>
<td>92</td>
<td></td>
</tr>
</tbody>
</table>
TABLE XI

EFFECT OF TRYPanOCIDAL DRUGS ON THE RESPIRATION OF T. BRUCEI

<table>
<thead>
<tr>
<th>Drug</th>
<th>Percent Change in Respiration in Comparison to Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0</td>
</tr>
<tr>
<td>Suramin</td>
<td>+110.3 ± 6.0</td>
</tr>
<tr>
<td>Antricyde</td>
<td>+ 6.1 ± 0.8</td>
</tr>
<tr>
<td>Ethidium Bromide</td>
<td>- 0.5 ± 0.1</td>
</tr>
<tr>
<td>Berenil</td>
<td>- 31.2 ± 2.4</td>
</tr>
</tbody>
</table>

The respiration was measured in the open steady state system we have previously described (12). Infected rats were treated with the trypanocidal drugs at 10 mg/kg. The trypanosomes were isolated at various times as noted in Table and used for respiratory studies. The differences expressed in comparison to controls represent the averages of three different experiments. Standard errors from these experiments are also given.
TABLE XII

Analysis of Amino Acids in SM Medium Before and After Growth of Trypanosoma rhodesiense EATRO 1895

<table>
<thead>
<tr>
<th>Amino Acid</th>
<th>Day Zero</th>
<th>Day 7</th>
<th>Percent Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lysine</td>
<td>2.25</td>
<td>1.03</td>
<td>-1.22</td>
</tr>
<tr>
<td>Tyrosine</td>
<td>0.28</td>
<td>0.07</td>
<td>-0.21</td>
</tr>
<tr>
<td>Glutamine + Glutamic Acid</td>
<td>1.40</td>
<td>2.76</td>
<td>+1.36</td>
</tr>
<tr>
<td>Aspartic Acid</td>
<td>5.96</td>
<td>1.00</td>
<td>-4.96</td>
</tr>
<tr>
<td>Phenylalanine</td>
<td>2.83</td>
<td>4.13</td>
<td>+1.30</td>
</tr>
<tr>
<td>Methionine</td>
<td>0.59</td>
<td>0.65</td>
<td>+0.06</td>
</tr>
<tr>
<td>Serine</td>
<td>0.41</td>
<td>0.66</td>
<td>+0.25</td>
</tr>
<tr>
<td>Proline</td>
<td>28.89</td>
<td>45.60</td>
<td>+16.71</td>
</tr>
<tr>
<td>Leucine</td>
<td>36.00</td>
<td>26.20</td>
<td>-9.40</td>
</tr>
<tr>
<td>Isoleucine</td>
<td>0.45</td>
<td>0.26</td>
<td>-0.19</td>
</tr>
<tr>
<td>Glycine</td>
<td>0.70</td>
<td>0.99</td>
<td>+0.29</td>
</tr>
<tr>
<td>Valine</td>
<td>1.71</td>
<td>1.76</td>
<td>+0.05</td>
</tr>
<tr>
<td>Alanine</td>
<td>7.61</td>
<td>13.21</td>
<td>+5.60</td>
</tr>
</tbody>
</table>
Figure Legends

Fig. 1. The site of action of various inhibitors on the nucleo-cell sap system and the mitochondrial system.

Fig. 2. T. brucei cultured infective trypomastigotes growing in the spaces between the buffalo lung tissue culture cells. The cells had been growing in culture for 25 days. The photograph of the trypanosomes on tissue culture cells were taken while they were alive. X200.

Fig. 3. Growth of T. brucei EATRO 110 on Chinese hamster lung tissue culture cells. The trypanosomes had been growing in vitro for 25 days. The trypanosomes are growing close to the tissue culture cells. X200.

Fig. 4. T. rhodesiense cultured infective trypomastigotes growing on the Chinese hamster lung cells. The cells were free-swimming in the medium and had been growing in culture for 25 days. X200.

Fig. 5. T. rhodesiense cultured infective trypomastigotes growing in the spaces between the tissue culture cells. The cells had been in culture for 25 days. X200.

Fig. 6. A and B. Giemsa stain of T. brucei. Note the subterminal position of the kinetoplast. The trypanosomes had been growing on buffalo lung tissue culture cells for 25 days. X1000.

Fig. 7. Electron micrograph of T. rhodesiense which was grown on Chinese hamster lung tissue culture cells for 60 days. Note the presence of the surface coat (SC), plasma membrane (pm), mitochondrion (M) and the microtubules (mt). The surface coat also surrounds the flagellum (F). X100,000.

Fig. 8. Electron micrograph of T. rhodesiense which was grown on Chinese hamster lung tissue culture cells for 60 days. The mitochondrion (M) has few cristae. Note the presence of the surface coat (SC) and the microbody (mb). X45,000.

Fig. 9. Electron micrograph of T. rhodesiense cultured infective trypomastigotes which had been maintained on Chinese hamster lung tissue culture cells for 80 days. The surface coat (SC), plasma membrane (pm) and microtubules (mt) are very distinct. X100,000.

Fig. 10. Electron micrograph of T. rhodesiense which was grown on Chinese hamster lung cells for 80 days. Note the presence of the surface coat. X100,000.

Fig. 11. Electron micrograph of T. rhodesiense slender bloodstream trypomastigotes. The surface coat is pronounced. (sc) surface coat; (pm) plasma membrane; (mt) microtubules; (F) flagellum. X100,000.
Fig. 12. Electron micrograph of *T. brucei* procyclic trypomastigote. Note the absence of the surface coat. (N) nucleus; (F) flagellum; (K) kinetoplast; (M) mitochondrion. X24,000.

Fig. 13. Electron micrograph of *T. brucei* bloodstream trypomastigotes. Note the presence of the surface coat. (K) kinetoplast. X24,000.

Fig. 14. Electron micrograph of *T. brucei* bloodstream trypomastigotes. Note the presence of the surface coat. X60,000.

Fig. 15. Steady state oxygen trace of *T. rhodesiense* bloodstream trypanosomes. The cell concentration was $1 \times 10^8$ cells.

Fig. 16. Steady state oxygen trace of *T. rhodesiense* cultured infective trypomastigotes maintained *in vitro* for 60 days on Chinese hamster lung tissue culture cells. The concentration was $1.0 \times 10^8$ cells.

Fig. 17. Steady state oxygen trace of *T. rhodesiense* procyclic trypomastigotes. The concentration of cells was $8.0 \times 10^7$ cells.

Fig. 18. Graph of infectivity test of cultured trypomastigotes of *T. brucei*. The control was a stabilate of *T. brucei* bloodstream forms. The cultured trypomastigotes had been maintained *in vitro* for 20 days on buffalo lung tissue culture cells.

Fig. 19. Electron micrograph of *T. brucei* EATRO 110 bloodstream trypomastigotes treated with berenil (10 mg/kg) for 90 minutes. A dyskinetoplastic trypanosome is present. X12,000.

Fig. 20. Electron micrograph of *T. brucei* EATRO 110 bloodstream trypomastigotes treated with berenil (10 mg/kg) for 90 minutes. There is a marked effect on the nuclear membrane and chromatin. X12,000.

Fig. 21. Electron micrograph of *T. brucei* EATRO 110 bloodstream trypomastigotes treated with berenil (10 mg/kg) for 90 minutes. This micrograph demonstrates the nucleus at several different stages of disruption or ultrastructure changes after treatment with berenil. X12,000.

Fig. 22. Effect of berenil on the growth of *T. brucei* in a rat. With treatment of berenil (5.0 mg/ml), trypanosomes are absent from the peripheral blood with 90 minutes.

Figs. 23 and 24. Electron micrographs of *T. brucei* EATRO 110 bloodstream trypomastigotes treated *in vivo* with ethidium bromide (10 mg/kg) for 2 hours. A dyskinetoplastic cell can be seen. X12,000.

Fig. 25. Electron micrograph of *T. brucei* EATRO 110 bloodstream trypomastigotes treated *in vivo* with ethidium bromide (10 mg/kg) for 2 hours. The nuclear membranes of the cells present show some effect of the drug. X12,000.

Fig. 26. Electron micrograph of *T. brucei* EATRO 110 bloodstream trypomastigotes treated *in vivo* with antrycide (10 mg/kg) for 12.4 hours. X12,000.
Fig. 27. *T. brucei* EATRO 110 bloodstream trypomastigotes treated in vivo with suramin (10 mg/kg) for 12½ hours. Little or no effect on the ultrastructure of the trypanosomes was observed. X12,000.

Fig. 28. *T. brucei* EATRO 110 trypomastigotes which were not treated with any drug. These cells represent the controls for the experiment discussed in Table VII. X12,000.

Fig. 29. Inhibition of $^3$H uridine incorporation in *T. brucei* EATRO 110 bloodstream trypomastigotes exposed to trypanocidal drugs in vivo. The concentration of the drugs used in all cases was 10 mg/kg.

Fig. 30. Inhibition of $^3$H leucine incorporation in *T. brucei* EATRC 110 bloodstream trypomastigotes exposed to trypanocidal drugs in vivo. The concentration of the drugs used in all cases was 10 mg/kg.

Fig. 31. Percent inhibition by ethidium bromide of RNA synthesis in *T. brucei* EATRO 110 bloodstream and procyclic trypomastigotes.

Fig. 32. Growth of *T. rhodesiense* in normal and modified SM medium.
(△--△) cells grown in SM medium (25 ml/140 ml volume);
(O--O) cells grown in modified SM medium (25 ml/140 ml volume);
(□--□) cells grown in modified SM medium (350 ml/855 ml volume).

Fig. 33. Procedure for *T. rhodesiense* DNA-cellulose $^{32}$P-RNA hybridization columns.

Figs. 34 and 35. Banding of cytoplasmic ribosomes from *T. brucei* procyclic trypomastigotes. The ribosomes were isolated in 50 mM Mg Cl$_2$ in TKM buffer in a gradient of 15 - 30% sucrose. The sample was spun for 18 hours at 40°C at 24,000 rpm. Some breakdown was observed when 10 mM Mg Cl$_2$ was used (Figure 35).

Fig. 36. Transformation experiment with *T. brucei* Lump 1026. The initial inoculum was from a rat at 2.1 x 10$^8$ cells/ml and a day 8 parasitemia. The trypanosomes had completely transformed from bloodstream to procyclic trypomastigotes within 72 hours.
Figure 2
Trypanosoma rhodesiense (bloodstream trypomastigotes)

- Cells
- 20 mM glucose
- 20 mM eGP
- 20 mM proline
- 4.5 mM azide
- 0.5 mM SHAM

Scale: 5 min.

Figure 15
Figure 16

* I. rhodesiense (cultured infective trypomastigotes)

- 20 mM glucose
- 4.5 mM azide
- 0.5 mM SHAM
- 20 mM proline
- Cells

Time: 5 min.
I. rhodesiense (procyclic trypomastigotes)

20 mM glucose
20 mM glut
0.5 mM SHAM
4.5 mM azide

240

120

5 min.
INFECTIVITY STUDIES OF CULTURED TRYPOMASTIGOTES

LEVEL OF INOCULUM

STABILATES
CULTURES

DAYS BEFORE DEATH

Figure 18
Figure 22

T. brucei

- - BERENIL TREATED, 5 mg/kg
- - CONTROL

NUMBER OF CELLS \times 10^9/ml

HOURS

60 65 70 75 80 85 90
Figure 25
Figure 29

*T. brucei* EATRO 110

$^3$H-URIDINE INCORPORATION

<table>
<thead>
<tr>
<th>MINUTES</th>
<th>RADIOACTIVITY (counts/min × 10^3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>20</td>
<td>4</td>
</tr>
<tr>
<td>30</td>
<td>6</td>
</tr>
<tr>
<td>40</td>
<td>8</td>
</tr>
<tr>
<td>50</td>
<td>10</td>
</tr>
<tr>
<td>60</td>
<td>12</td>
</tr>
</tbody>
</table>

CONTROL

ETHIDIUM BROMIDE

ANTRYCIDE

BERENIL

SURAMIN
Figure 30

T. brucei EATRO II0

\( \text{\textsuperscript{3}H-Leucine Incorporation} \)

- CONTROL
- ETHIDlUM BROMIDE
- BERENIL
- ANTRYCIDE

RADIOACTIVITY (counts/min \( \times 10^3 \))

MINUTES

0 10 20 30 40 50 60
Figure 31
Figure 32

*T. rhodesiense* in SM (Normal and Modified) + 10% FBS

**Graph:**
- Y-axis: Trypanosomes x 10^6/ml of culture
- X-axis: Hours

Data points at:
- 0 hours: 0
- 24 hours: 0.1
- 48 hours: 0.25
- 72 hours: 0.5
- 96 hours: 1.0
- 120 hours: 2.5
- 144 hours: 10.0

Legend:
- Circles: O
- Squares: □
- Triangles: △
$^{32}\text{P-RNA}$

A = NUCLEAR DNA - RANDOM SEQUENCES

B = KINETOPLAST DNA - MINICIRCLE SEQUENCES

C = KINETOPLAST DNA - MAXICIRCLE SEQUENCES

Figure 33
T. brucei PROCYCLIC TRYPOMASTIGOTE RIBOSOMES

10mM MgCl₂

ABSORBANCE - 254 nm

Figure 35
Figure 36

T. brucei Lump 1026 TRANSFORMATION

TRYPANOSOMES \times 10^6/ml OF CULTURE

HOURS

PERCENT TRANSFORMATION

0 20

0 40

0 60

0 80

0 100

0 120